Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens

Clinical Colorectal Cancer

Volumn 10, Issue 3, 2011, Pages 203-206

  Saam, Jennifer ^a   Critchfield, Gregory C ^a   Hamilton, Stephanie A ^a   Roa, Benjamin B ^a   Wenstrup, Richard J ^a   Kaldate, Rajesh R ^a  

^a Utah   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

AREA UNDER THE CURVE; BODY SURFACE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COHORT ANALYSIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; NOTE;

EID: 80052463879     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.03.015     Document Type: Note

References (16)

1. M. Saif, A. Choma, and S. Salamone Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes J Natl Cancer Inst 101 2009 1543 1552
2. G. Milano, M.C. Etienne, and E. Cassuto-Viguier Influence of sex and age on fluorouracil clearance J Clin Oncol 10 1992 1171 1175
3. E. Gamelin, M. Boisdron-Celle, and V. Guérin-Meyer Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage J Clin Oncol 17 1999 1105
4. E. Gamelin, R. Delva, and J. Jacob Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer J Clin Oncol 26 2008 2099 2105
5. M. Gusella, A.C. Frigo, and C. Bolzonella Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer Br J Cancer 100 2009 1549 1557
6. E.C. Gamelin, E.M. Danquechin-Dorval, and Y.F. Dumesnil Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU Cancer 77 1996 441 451 (Pubitemid 26047564)
7. M. Ychou, J. Duffour, and A. Kramar Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using bimonthly pharmacokinetically intensified LV5FU2 regimen Cancer Chemother Pharmacol 52 2003 282 290 (Pubitemid 37352594)
8. B.L. Hillcoat, P.B. McCulloch, and A.T. Figueredo Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion Br J Cancer 38 1978 719 724 (Pubitemid 9086482)
9. A. Di Paolo, M. Lencioni, and F. Amatori 5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer Clin Cancer Res 14 2008 2749 2755
10. J.L. Au, Y.M. Rustum, and E.J. Ledesma Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas Cancer Res 42 1982 2930 2937 (Pubitemid 12085770)
11. C.J. van Groeningen, H.M. Pinedo, and J. Heddes Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule Cancer Res 48 1988 6956 6961 (Pubitemid 19012233)
12. T. Yoshida, E. Araki, and M. Iigo Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer Cancer Chemother Pharmacol 26 1990 352 354 (Pubitemid 20271539)
13. D.L. Trump, M.J. Egorin, and A. Forrest Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole J Clin Oncol 9 1991 2027 2035
14. E. Gamelin, M. Boisdron-Celle, and R. Delva Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients J Clin Oncol 16 1998 1470 1478 (Pubitemid 28175768)
15. J.H. Beumer, M. Boisdron-Celle, and W. Clarke Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer Ther Drug Monit 31 2009 688 694
16. G. Milano, M.C. Etienne, and N. Renee Relationship between fluorouracil systemic exposure and tumor response and patient survival J Clin Oncol 12 1994 1291 1295 (Pubitemid 24173946)